The Permanent Representative to the EU told how the attitude towards the Sputnik V vaccine has changed

BRUSSELS, 11 Feb – RIA Novosti. The attitude to the Russian vaccine against the Sputnik V coronavirus in the European Union has recently changed from suspicious and even hostile to almost enthusiastic, Russian Permanent Representative to the EU Vladimir Chizhov told reporters in Brussels.

“We watched with interest how the attitude here, in the European Union, to the Russian drug, which for several months, that is practically from the moment of its appearance, was perceived with undisguised suspicion, if not hostility, was changing. And all this has now been replaced by wording that Sputnik V is Russia's biggest scientific achievement almost since the launch of the first artificial Earth satellite in 1957, “he explained.

A senior Russian diplomat sees in this change of position not just an “epiphany,” but the realization that Western vaccines do not guarantee success. “Probably, behind this there is not just an epiphany regarding the merits of our vaccine. It was realized that the alternative options, namely vaccines from Western countries, for the supply of which the European Commission signed half a dozen contracts and paid an advance payment of 2 billion 700 million euros, have not received adequate the volume of supplies in return does not guarantee success, “Chizhov stressed.

In his opinion, this confirms the Russian position that “in a pandemic it is necessary not to engage in rivalry, not to organize a vaccine race, but to establish broad international cooperation in order to overcome the pandemic, to wage a joint non-politicized and non-ideological struggle with our common enemy, which is this coronavirus.” …

Answering the question of when the European Union will approve the Russian vaccine, Russia's Permanent Representative to the EU noted that no one can name the date now, but “the process has begun.” “As far as I know, the Russian Direct Investment Fund (RDIF), which promotes our vaccine to foreign markets, is in contact with the said agency (European Medicines Agency, EMA) and is leading the case to register Sputnik V in the European Union. will take this registration, at the moment, apparently, no one can predict, but the process, as they liked to say in our country, has begun. I think that all parties are interested in bringing it to the end, “Chizhov concluded.

The developer of the Russian vaccine against coronavirus Sputnik V is currently negotiating with the European drug regulator EMA to register the vaccine on the EU market (obtain a marketing authorization).

Earlier, the agency told RIA Novosti that the developer has received the necessary scientific advice and can prepare an application for consideration of obtaining a registration certificate. Later, RDIF said that the application for registration of the Sputnik V vaccine was submitted to the EU on January 29 and they have confirmation that the application was accepted. The Sputnik V Twitter account posted an extract about the application for vaccine registration in the EU. However, EMA noted that as of Wednesday, February 10, the agency “had not received an application for rolling revew or marketing autorisation for the Sputnik V vaccine developed by the National Epidemiology Research Center. and Microbiology named after NF Gamaleya “.

If a conditional marketing authorization is issued and approved by the European Commission, the Russian vaccine can be centrally supplied to the EU. The European Union, even before the appearance of the first approved vaccines against coronavirus, made a decision on their centralized procurement. In total, contracts were signed with six manufacturers.

Currently, vaccines from Pfizer / BioNTech (purchase up to 600 million doses), Moderna (160 million doses) and AstraZeneca (up to 400 million doses) are authorized in the EU market. In addition, the EC entered into contracts for the supply of vaccines to the EU with Johnson & Johnson, Sanofi-GSK, CureVac. Until now, these developers have not yet submitted applications for the authorization of their drugs on the EU market, but an application from J&J is expected in the near future.

Thus, thanks to the contracts of the European Commission, the EU countries will be able to get access to more than 2.3 billion doses of anti-coronavirus vaccines. The EU expects that by the end of the summer in Europe, about 70% of the population will already be vaccinated.

In recent weeks, the EU has faced several challenges in the supply of allied vaccines from Pfizer / BioNTech and AstraZeneca. Delays in deliveries could derail Brussels' ambitious vaccination plans.

Hungary recently approved the Russian Sputnik V vaccine for use in the country and signed an agreement with its manufacturer for the supply of the drug. More and more interest in the Russian vaccine is shown in other countries of the European Union.

Earlier, an official from the European Commission said that the EU already has a sufficient portfolio of orders for vaccines against COVID-19, which allows the entire population of the Union to be vaccinated. At the same time, he said, Brussels does not close its doors for new vaccine manufacturers.

Author: wedocount

Leave a Reply

Your email address will not be published. Required fields are marked *